These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 16293866

  • 1. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS.
    J Clin Oncol; 2005 Nov 20; 23(33):8362-70. PubMed ID: 16293866
    [Abstract] [Full Text] [Related]

  • 2. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J.
    J Clin Oncol; 2008 Mar 01; 26(7):1128-34. PubMed ID: 18309948
    [Abstract] [Full Text] [Related]

  • 3. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 4. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR.
    Int J Radiat Oncol Biol Phys; 2014 Feb 01; 88(2):312-8. PubMed ID: 24411602
    [Abstract] [Full Text] [Related]

  • 5. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 01; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer.
    Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, Maldonado A, García de Barajas S, Calero-García R, Pozo MA, Martín-Escribano P, Martín-García I, García-Lujan R, Lopez-Encuentra A, Arenas de Pablo A.
    J Clin Oncol; 2005 Nov 20; 23(33):8348-56. PubMed ID: 16219937
    [Abstract] [Full Text] [Related]

  • 9. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, Kucharczuk JC, Lin L, Rengan R.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):340-7. PubMed ID: 22104359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ, Wang SX, Zhong WZ, Xu CR, Yan HH, Wu YL.
    Nucl Med Commun; 2011 Dec 01; 32(12):1113-20. PubMed ID: 21934546
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H, Wroblewski K, Pu Y.
    Acta Radiol; 2012 Jun 01; 53(5):561-8. PubMed ID: 22661603
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy.
    Lee HY, Choi WH, Yoo IR, Park JK, Sung SW, Kim YS, Kang JH.
    Asia Pac J Clin Oncol; 2020 Feb 01; 16(1):70-74. PubMed ID: 31782256
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
    Trister AD, Pryma DA, Xanthopoulos E, Kucharczuk J, Sterman D, Rengan R.
    Am J Clin Oncol; 2014 Apr 01; 37(2):135-9. PubMed ID: 23111361
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
    Banna GL, Anile G, Russo G, Vigneri P, Castaing M, Nicolosi M, Strano S, Gieri S, Spina R, Patanè D, Calcara G, Fraggetta F, Marletta F, Stefano A, Ippolito M.
    Oncology; 2017 Apr 01; 92(1):39-47. PubMed ID: 27832654
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.